The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare
Bone · 2024
DOI: 10.1016/j.bone.2023.116954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone, 2024. Verfasst von Ye Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: yeliu@uab.edu. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, COVID-19, Osteoporosis, Postmenopausal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: University of Alabama at Birmingham.
Abstract (Originalsprache)
PURPOSE: To evaluate the impact of the COVID lock-down on treatment interruptions of romosozumab, a first in class biologic therapy, administered by healthcare providers once monthly. METHODS: We used Medicare data from 1/1/2017 to 9/30/2021 to identify women age ≥65 initiating romosozumab between 4/1/2019 and 6/30/2021. Patient demographics, provider specialty, and baseline comorbidities were identified. Romosozumab dispensations were grouped into five 6-month periods based on the dispensing date from FDA licensure to the end of the data (Period 1 to 5). "Treatment interruption" was defined as any interval gap between 2 dispensations >60 days. The numbers of treatment interruption event were aggregated per period per patient. Mixed effect Poisson regression with patient-level random effects was performed, including an interaction term between Period and number of prior doses. RESULTS: There were 12,216 romosozumab new users identified. A total of 2724 treatment interruption events were identified among 2229 romosozumab users. After adjustment, comparing with the period immediately before the lockdown (Period 2: 2019-10-1-2020-3-30), the IRRs (95 % CI) for treatment interruption were 0.49 (0.29, 0.81), 1.65 (1.48, 1.85), 1.79 (1.60, 2.01), and 1.67 (1.49, 1.87) for periods 1, 3, 4, and 5, respectively, per 1 prior dose change (p < 0.01 for all IRRs), where Periods 3, 4, and 5 were post-lockdown. CONCLUSION: Compared to the pre-COVID period, the lockdown negatively impacted the continuity of romosozumab treatment among Medicare beneficiaries. Prioritizing in-time assistance for patients receiving a provider-administered parenteral therapy is critical when patients' in-person access to their provider is compromised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: yeliu@uab.edu.
- Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
- University of Alabama at Birmingham, Birmingham, AL, USA.
- University of Alabama at Birmingham, Birmingham, AL, USA; Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, USA.
Förderung
- University of Alabama at Birmingham
Zitieren
APA
Liu, Y., Arora, T., Zhang, J., Sodhi, S. K., Xie, F., & Curtis, J. R. (2024). The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare. Bone. https://doi.org/10.1016/j.bone.2023.116954
Vancouver
Liu Y, Arora T, Zhang J, Sodhi SK, Xie F, Curtis JR. The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare. Bone. 2024. doi:10.1016/j.bone.2023.116954
BibTeX
@article{Liu2024,
author = {Liu, Ye and Arora, Tarun and Zhang, Jingyi and Sodhi, Sandeep K and Xie, Fenglong and Curtis, Jeffrey R},
title = {The interruption of romosozumab treatment during COVID lockdown among US post-menopausal women enrolled in Medicare},
journal = {Bone},
year = {2024},
doi = {10.1016/j.bone.2023.116954}
}
EUVIMED